Migraine life-time prevalence in mental disorders: concurrent comparisons with first-degree relatives and the general population.

The authors quantified the prevalence of migraine in subjects with mental disorders, first-degree relatives and the adult general population (GP) in Mérida, Venezuela. After validation, a modified, short version of the Lipton's diagnostic scale was administered to consecutively admitted in- and out-patients (n = 1059), their first-degree relatives (n = 445) and a probabilistic sample of the GP (n = 516). In the GP, the frequency of migraine (percentage and 95% confidence interval) was 14.9 (11.8-17.9). The migraine frequencies were (percentage and odd ratio probability against the GP: bipolar disorder (15.7%, p = 0.5), schizophrenia (8.3%, p = 0.08), depression and dysthimia (24.4%, p = 0.2), anxiety disorders (10.0%, p = 0.02), personality disorders (11.4%, p = 0.15), all other disorders (15.5%, p = 0.4), relatives of bipolar patients (4.4%, p < 0.001), relatives of schizophrenia patients (3.5%, p = 0.003), and relatives of patients with all other mental disorders (12.8%, p = 0.4). Migraine was more common in women (p < 0.001), and the bipolar patients presented the highest female to male ratio (8:1). A high variability was observed in migraine prevalence among the diagnostic categories, but it was particularly high in subjects with affective disorders, mainly in women, who thus deserve special attention from clinicians.

Migraine life-time prevalence in mental disorders: concurrent comparisons with first-degree relatives and the general population / Prevalencia de migraña en trastornos mentales: comparación concurrente con familiares de primer grado y con la población general

The authors quantified the prevalence of migraine in subjects with mental disorders, first-degree relatives and the adult general population (GP) in Mérida, Venezuela. After validation, a modified, short version of the Lipton’s diagnostic scale was administered to consecutively admitted in- and out-patients (n = 1059), their first-degree relatives (n = 445) and a probabilistic sample of the GP (n = 516). In the GP, the frequency of migraine (percentage and 95% confidence interval) was 14.9 (11.8-17.9). The migraine frequencies were (percentage and odd ratio probability against the GP: bipolar disorder (15.7%, p = 0.5), schizophrenia (8.3%, p = 0.08), depression and dysthimia (24.4%, p = 0.2), anxiety disorders (10.0%, p = 0.02), personality disorders (11.4%, p = 0.15), all other disorders (15.5%, p = 0.4), relatives of bipolar patients (4.4%, p < 0.001), relatives of schizophrenia patients (3.5%, p = 0.003), and relatives of patients with all other mental disorders (12.8%, p = 0.4). Migraine was more common in women (p < 0.001), and the bipolar patients presented the highest female to male ratio (8:1). A high variability was observed in migraine prevalence among the diagnostic categories, but it was particularly high in subjects with affective disorders, mainly in women, who thus deserve special attention from clinicians.

Los autores cuantificaron la prevalencia de migraña en sujetos con trastornos mentales, sus familiares de primer grado y la población general (PG) en Mérida, Venezuela. Se utilizó una versión abreviada de la escala diagnostica de Lipton. Luego de un estudio de validez, tal escala se administró a pacientes ambulatorios u hospitalizados atendidos en forma consecutiva (n = 1.059), a sus familiares de primer grado (n = 445) y a una muestra probabilística de la PG (n = 516). La frecuencia de migraña en la PG (porcentaje e intervalo de confianza de 95%) fue de 14,9 (11,8-17,9). La frecuencia para los diversos trastornos (porcentaje y probabilidad asociada a la razón de momios (odds ratio) con respecto a la PG) fue: trastorno bipolar (15,7%, p = 0,5), esquizofrenia (8,3%, p = 0,08), depresión y distimia (24,4%, p = 0,2), trastornos de ansiedad (10,0%, p = 0,02), trastornos de personalidad (11,4%, p = 0,15), todos los otros trastornos (15,5%, p = 0,4). En los familiares, la frecuencia fue: trastorno bipolar (4,4%, p < 0,001), esquizofrenia (3,5%, p = 0,003), otros trastornos (12,8%, p = 0,4). El diagnóstico de migraña fue más frecuente en mujeres (p < 0,001), y los sujetos con trastorno bipolar presentaron el mayor índice mujer:hombre (8:1). Se observó una alta variabilidad en la prevalencia de migraña en las diversas categorías diagnósticas. Tal frecuencia fue particularmente elevada en sujetos con trastornos afectivos, principalmente en mujeres, las cuales ameritan una atención especial por parte de los médicos tratantes.

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.

OBJECTIVE: To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine. METHOD: Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n = 20; 850 to 1700 mg daily) or placebo (n = 20) group in a 14-week double-blind study. Waist circumference (WC), BWG, body mass index (BMI) fasting glucose, insulin, and lipids were evaluated at baseline and at Weeks 7 and 14 of treatment. RESULTS: At Week 14, BWG (kg) was similar in the metformin group (5.5 kg) and the placebo group (6.3 kg), P = 0.4. There were no differences between the changes in BMI, WC, glucose, insulin, insulin resistance index (HOMA-IR), and plasma lipid levels observed in the treatment group and the placebo group; however, glucose levels decreased significantly after metformin administration (P = 0.02). The HOMA-IR decreased significantly in both groups, but 3 subjects from the placebo group developed fasting glucose levels greater than 5 mmol/L. After taking metformin, triglyceride levels increased, but the cholesterol profile improved significantly. CONCLUSIONS: Metformin did not prevent olanzapine-induced BWG. While some lipid parameters worsened during placebo, the HOMA-IR improved in both the placebo and the metformin groups. Carbohydrate metabolism impairment was not systematically observed during short-term olanzapine administration.